| Style | Citing Format |
|---|---|
| MLA | Yoo SGK, et al.. "Glp-1 Receptor Agonists for Obesity: Eligibility Across 99 Countries." The Lancet Diabetes and Endocrinology, vol. 14, no. 2, 2026, pp. 105-108. |
| APA | Yoo SGK, Teufel F, Theilmann M, Si Y, Toure EA, Aryal K, Barnighausen T, Bait A, Barreto M, Bovet P, Brant LCC, Cuschieri S, Damasceno A, Farzadfar F, Fawwad A, Geldsetzer P, Hambleton IR, Houehanou C, Howitt C, ... Mannegoehler J (2026). Glp-1 Receptor Agonists for Obesity: Eligibility Across 99 Countries. The Lancet Diabetes and Endocrinology, 14(2), 105-108. |
| Chicago | Yoo SGK, Teufel F, Theilmann M, Si Y, Toure EA, Aryal K, Barnighausen T, et al.. "Glp-1 Receptor Agonists for Obesity: Eligibility Across 99 Countries." The Lancet Diabetes and Endocrinology 14, no. 2 (2026): 105-108. |
| Harvard | Yoo SGK et al. (2026) 'Glp-1 Receptor Agonists for Obesity: Eligibility Across 99 Countries', The Lancet Diabetes and Endocrinology, 14(2), pp. 105-108. |
| Vancouver | Yoo SGK, Teufel F, Theilmann M, Si Y, Toure EA, Aryal K, et al.. Glp-1 Receptor Agonists for Obesity: Eligibility Across 99 Countries. The Lancet Diabetes and Endocrinology. 2026;14(2):105-108. |
| BibTex | @article{ author = {Yoo SGK and Teufel F and Theilmann M and Si Y and Toure EA and Aryal K and Barnighausen T and Bait A and Barreto M and Bovet P and Brant LCC and Cuschieri S and Damasceno A and Farzadfar F and Fawwad A and Geldsetzer P and Hambleton IR and Houehanou C and Howitt C and Jrgensen J and Gonzalezrivas JP and Labadarios D and Marcus M and Martins J and Mwalim O and Nietomartinez R and Odili AN and Orazumbekova B and Perman G and Quesnelcrooks S and Moghaddam SS and Sewpal R and Sousauva M and Sulola MA and Venkataraman K and Vollmer S and Xueling S and Atun R and Banegas JR and Franco JVA and Arnott C and Chandiwana N and Huffman MD and Davies J and Ali MK and Flood D and Mannegoehler J}, title = {Glp-1 Receptor Agonists for Obesity: Eligibility Across 99 Countries}, journal = {The Lancet Diabetes and Endocrinology}, volume = {14}, number = {2}, pages = {105-108}, year = {2026} } |
| RIS | TY - JOUR AU - Yoo SGK AU - Teufel F AU - Theilmann M AU - Si Y AU - Toure EA AU - Aryal K AU - Barnighausen T AU - Bait A AU - Barreto M AU - Bovet P AU - Brant LCC AU - Cuschieri S AU - Damasceno A AU - Farzadfar F AU - Fawwad A AU - Geldsetzer P AU - Hambleton IR AU - Houehanou C AU - Howitt C AU - Jrgensen J AU - Gonzalezrivas JP AU - Labadarios D AU - Marcus M AU - Martins J AU - Mwalim O AU - Nietomartinez R AU - Odili AN AU - Orazumbekova B AU - Perman G AU - Quesnelcrooks S AU - Moghaddam SS AU - Sewpal R AU - Sousauva M AU - Sulola MA AU - Venkataraman K AU - Vollmer S AU - Xueling S AU - Atun R AU - Banegas JR AU - Franco JVA AU - Arnott C AU - Chandiwana N AU - Huffman MD AU - Davies J AU - Ali MK AU - Flood D AU - Mannegoehler J TI - Glp-1 Receptor Agonists for Obesity: Eligibility Across 99 Countries JO - The Lancet Diabetes and Endocrinology VL - 14 IS - 2 SP - 105 EP - 108 PY - 2026 ER - |